RAPT Therapeutics Inc

RAPT insiders sell 30k+ shares after GSK merger: learn what the $58‑share premium, reduced insider stake and post‑merger prospects mean for investors.

RAPT Therapeutics insider sales reveal a smooth merger with Redrose/GlaxoSmithKline—insiders liquidate RSUs at $58, confirming a planned exit without dilution, while investors see stable cap and a positive outlook for post‑merger growth.